BURLINGTON, Mass., July 23, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced that it will issue its financial results for the second quarter of 2014 on Monday, August 4, 2014, prior to the market open.
Aldeyra will hold a conference call on Monday, August 4, 2014, at 8:30 a.m. ET. Dr. Todd Brady, President and Chief Executive Officer, and Stephen Tulipano, Chief Financial Officer, will host the conference call to discuss Aldeyra's financial results for the second quarter 2014 and provide a general business update. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13587511. A live webcast of the conference call will also be available on the investor relations page of Aldeyra's corporate website at www.aldeyra.com.
After the live webcast, the event will remain archived on Aldeyra's website for one year. In addition, a telephonic replay of the call will be available until August 18, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13587511.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com
CONTACT: Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 617-308-2374 firstname.lastname@example.org Investor Contact: David Burke/Lee Roth The Ruth Group Tel: +1 646-536-7009/7012 email@example.comfirstname.lastname@example.orgSource:Aldeyra Therapeutics